Business
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
CAMBRIDGE, Mass., June 03, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced the issuance of a new U.S. patent (USPTO Number 12,187,679). The patent strengthens Enveric’s intellectual property portfolio and covers a structurally diverse class of novel molecules with potential therapeutic applic
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/221fa3c6e7f3246b272bf1cb04c3e7d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/deI9Mngnpu608pAHizg3PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/221fa3c6e7f3246b272bf1cb04c3e7d6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_qQxeW0QcHh2D9D7TRddZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/221fa3c6e7f3246b272bf1cb04c3e7d6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"New Intellectual Property Unlocks Potential for Sleep and CNS Therapeutics","length":74,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., June 03, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced the issuance of a new U.S. patent (USPTO Number 12,187,679). The patent strengthens Enveric’s intellectual property portfolio and covers a structurally diverse class of novel molecules with potential therapeutic applications in the treatment of sleep and central nervous system (CNS) disorders.","length":613,"tagName":"p"},{"type":"text","content":"The newly granted patent, titled, "Hydroxylated Psilocybin Derivatives and Methods of Using," expands Enveric’s proprietary drug discovery platform and includes a unique subset of compounds that demonstrate selective binding to the melatonin MT1 receptor—an established, therapeutic target known to regulate circadian rhythm and sleep-wake cycles. These molecules were identified through Enveric’s structure-activity screening efforts.","length":445,"tagName":"p"},{"type":"text","content":"Melatonin signaling is a clinically validated pathway in the treatment of sleep and mood disorders. Several approved therapies leverage this mechanism of action, including ramelteon (Rozerem®), a selective MT1/MT2 agonist approved by the FDA for insomnia, and agomelatine (Valdoxan®), an MT1/MT2 agonist and 5-HT₂C antagonist a...